| Title |
Novel Oral Anticoagulants for Stroke Prevention in the Geriatric Population
|
|---|---|
| Published in |
American Journal of Cardiovascular Drugs, November 2013
|
| DOI | 10.1007/s40256-013-0050-3 |
| Pubmed ID | |
| Authors |
Daniel Kim, Richard Barna, Mary Barna Bridgeman, Luigi Brunetti |
| Abstract |
Prior to the availability of several newer anticoagulant medications, there had been no new advances in anticoagulation management for stroke prevention since the advent of warfarin in the 1950s. The availability of the novel oral anticoagulants (NOACs) dabigatran, rivaroxaban,and apixaban represent improvements over warfarin in many respects, including the elimination of the need for therapeutic drug monitoring, fewer drug and food interactions,and favorable efficacy; however, these agents are not without risk. Specifically, the use of the NOACs in the geriatric population, who are more likely to have an increased risk of stroke due to atrial fibrillation and other medical comorbidities, is not without risk. The objective of this review is to update the clinician on the use of the NOACs in the geriatric population and introduce the controversies and risks surrounding these newer therapies. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 2% |
| Slovenia | 1 | 2% |
| Switzerland | 1 | 2% |
| Unknown | 56 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 17% |
| Student > Bachelor | 8 | 14% |
| Student > Postgraduate | 6 | 10% |
| Student > Ph. D. Student | 6 | 10% |
| Researcher | 5 | 8% |
| Other | 11 | 19% |
| Unknown | 13 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 53% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 12% |
| Economics, Econometrics and Finance | 2 | 3% |
| Computer Science | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 16 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2014.
All research outputs
#15,286,644
of 22,733,113 outputs
Outputs from American Journal of Cardiovascular Drugs
#308
of 425 outputs
Outputs of similar age
#130,334
of 212,312 outputs
Outputs of similar age from American Journal of Cardiovascular Drugs
#5
of 8 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 425 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,312 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.